Welcome to our dedicated page for Albemarle SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating lithium volume forecasts or bromine pricing clauses in Albemarle’s 250-page reports can feel overwhelming. Stock Titan solves this by turning Albemarle’s complex SEC filings into clear, actionable insight—so you can focus on decisions, not document hunts.
Every filing is here in real time, from the Albemarle annual report 10-K simplified to the latest Albemarle quarterly earnings report 10-Q filing. Our AI surfaces segment-level EBITDA, capex plans for Chilean brine assets, and risk factors tied to lithium prices—without scrolling through footnotes. Need to monitor management moves? Receive instant alerts on Albemarle insider trading Form 4 transactions and track Albemarle Form 4 insider transactions real-time to spot buying or selling patterns ahead of material events.
Common questions are answered in-line: “How do I understand Albemarle SEC documents with AI?” Simply open any 8-K; our summary explains the supply-contract or environmental update in plain English. Curious about leadership pay? The Albemarle proxy statement executive compensation section highlights equity awards and performance metrics. Need context on sudden news? The platform links each Albemarle 8-K material events explained summary to prior disclosures, giving you timeline clarity in seconds.
Whether you’re reviewing catalysts margins, tracking debt covenants, or comparing Albemarle earnings report filing analysis across quarters, Stock Titan provides:
- AI-powered summaries that explain every form in simple terms
- Real-time EDGAR updates across 10-K, 10-Q, 8-K, S-8, and more
- Instant access to Albemarle executive stock transactions Form 4
- Downloadable data tables for quick model inputs
Spend less time parsing disclosures and more time understanding how Albemarle converts critical resources into shareholder value.
Albemarle Corporation (ALB) – Form 4 Insider Transaction
Director James J. O’Brien reported two share acquisitions dated 1 July 2025:
- 2,725 common shares granted as the annual installment of non-employee director compensation under the company’s 2023 Stock Compensation and Deferral Election Plan. These shares are scheduled to vest on 1 July 2026.
- 37 common shares issued in lieu of cash dividends that accrued on a prior award granted 1 July 2024 and fully vested on 1 July 2025.
Both transactions were reported with a $0.00 acquisition price, indicating they are equity compensation rather than open-market purchases. Following the two grants, O’Brien’s direct beneficial ownership increased to 8,085 common shares.
No derivative securities were reported and no dispositions occurred. An Exhibit 24 Power of Attorney was filed to authorize the attorney-in-fact signature.
The filing is routine, reflecting scheduled director equity awards rather than discretionary insider buying or selling.
Albemarle Corporation (ALB) – Form 4 insider filing dated 07/03/2025
Non-employee director Alejandro Daniel Wolff reported two routine equity transactions carried out under the company’s 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors:
- Common stock dividend equivalents: 37 shares were credited on 07/01/2025 as dividend equivalents on a prior equity award that vested the same day. These shares were acquired at $0 cost, bringing the director’s directly held common stock to 12,539 shares.
- Phantom stock grant: 2,725 phantom stock units (1-for-1 convertible into common shares) were awarded on 07/01/2025. The units vest on 07/01/2026 and have no stated expiration date. Including this grant and associated dividend equivalents, the director now holds 6,278 phantom stock units.
No sales or dispositions were reported. The transactions were made at $0 price and do not involve open-market purchases or sales. As Wolff remains on the board, these grants represent standard annual director compensation and dividend accruals rather than signal-bearing insider buying or selling.
Overall, the filing reflects normal course equity accrual that slightly increases insider alignment but is immaterial to Albemarle’s share count or valuation. There is no indication of strategic intent or upcoming corporate events.
Albemarle Corporation (ALB) – Form 4 insider transaction filing
Director Dean Seavers reported two equity awards dated 1 July 2025:
- 2,725 common shares granted under the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors; the award vests on 1 July 2026.
- 37 additional shares issued as accrued dividends on a July 2024 award that vested in full on 1 July 2025.
No shares were sold and no derivative securities were transacted. Following the awards, Seavers’ total direct beneficial ownership rose to 12,021 common shares. The transactions were effected at a stated price of $0, reflecting their nature as board compensation rather than open-market purchases.
The filing is routine for annual director compensation but does increase insider equity alignment and signals continued board participation in Albemarle’s long-term incentive structure.
FAQ
What is the current stock price of Albemarle (ALB)?
What is the market cap of Albemarle (ALB)?
